Oncolyze is an early stage biotech that is focused on partnering with academic institutions, cancer centers and companies that share an equal inquisitiveness, drive and enthusiasm for developing and commercializing transformational products that may deliver a significant benefit to cancer patients. Such collaborations allow us to leverage external skillsets, mitigate risk inherent in the drug development process, accelerate development of our drugs, and potentially generate non-dilutive cash through milestones, royalties and ultimately direct sales.
We either have active research partnerships or have previously collaborated with some of the world’s top academic institutions and cancer centers:
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. It has been named one of the nation’s top two cancer hospitals by the U.S. News & World Report since the survey’s inception in 1990.
Founded in 1913, City of Hope is one of only 49 comprehensive cancer centers in the nation, as designated by the National Cancer Institute. Over the decades, research conducted at City of Hope has led to significant advances in modern medicine, including the development of the first synthetic human insulin, human growth hormone and the technology behind the widely used cancer-fighting drugs Herceptin, Rituxan and Avastin.
Today, SUNY Downstate is one of the nation's leading urban medical centers. As the only academic medical center in Brooklyn, we serve a large population – over 2.3 million people – and one that is among the most diverse in the world. We are also an engine of opportunity for students interested in pursuing careers in health care.
TGen, the Translational Genomics Research Institute, is an affiliate of City of Hope. We work to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders. By identifying treatment options in this manner, we believe medicine becomes more rational, more precise and, well, more personal.
Moffitt Cancer Center is the only NCI-designated Comprehensive Cancer Center based in Florida. With its singular focus on cancer, Moffitt has worked tirelessly in the areas of patient care, research and education since opening in Tampa in 1986. Moffitt’s research focuses on cutting-edge discoveries that can be rapidly translated into improved diagnostic, preventive and therapeutic advances.
Today, with more than 1,000 medical students, Drexel University College of Medicine is educating 1 in every 83 medical students in the nation. Graduate students number more than 850, and the College is the academic partner in the education of more than 550 medical residents and fellows. There are more than 700 clinical and basic science faculty, and more than 1,700 affiliate and volunteer faculty.
Our novel approach has realized exciting preclinical results. We hope that such early signs of efficacy, with selective targeting of cancer cells, translate to a dramatic breakthrough treatment for AML patients, as well as patients with one or more other hematologic and solid cancers. Should our hypothesis prove successful, therapeutics exploiting this mechanism of action may be a huge step to, dare we say, curing AML and certain other cancers.
If you have an interest in licensing OM-301 or our technology, or partnering with us for the development and/or commercialization in any way, please do not hesitate to reach out to us at firstname.lastname@example.org to learn more.